NeuroPace makes and sells the RNS System, a brain-implanted device that treats drug-resistant epilepsy. The RNS System is the only closed-loop neuromodulation device on the market: it continuously monitors the brain's electrical activity, detects abnormal patterns in real time, and delivers targeted electrical pulses to prevent seizures before they occur. Unlike competing devices, the RNS System records and stores intracranial EEG data, which clinicians use to monitor patients remotely and fine-tune therapy over time. NeuroPace sells the RNS System directly to epileptologists and neurosurgeons at specialized epilepsy centers through a direct sales force. Revenue comes from initial implant procedures (the primary growth driver) and replacement procedures when the device battery reaches end of service after roughly 11 years. RNS gross margins run above 80%. NeuroPace also distributes SEEG diagnostic products, though that business is being wound down, and generates modest revenue from data licensing agreements with pharma companies. NeuroPace's growth strategy centers on deeper penetration of existing epilepsy centers, expanding into community-based settings through its Project CARE initiative, and pursuing FDA approval for new indications. The RNS System is currently approved only for adults with drug-resistant focal epilepsy; NeuroPace has filed for approval in idiopathic generalized epilepsy and is pursuing a pediatric indication. NeuroPace also has a growing database of iEEG records, which the company is beginning to monetize through pharma data partnerships and AI-powered clinical tools.